These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
159 related items for PubMed ID: 39342325
1. Inflammatory and immune variables as predictors of survival in dogs with myxomatous mitral valve disease. Cimerman M, Druzhaeva N, Nemec Svete A, Hajdinjak M, Pohar K, Ihan A, Domanjko Petrič A. BMC Vet Res; 2024 Sep 28; 20(1):431. PubMed ID: 39342325 [Abstract] [Full Text] [Related]
2. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease. Druzhaeva N, Nemec Svete A, Ihan A, Pohar K, Domanjko Petrič A. J Vet Intern Med; 2021 Sep 28; 35(5):2112-2122. PubMed ID: 34236111 [Abstract] [Full Text] [Related]
4. Selected hematological, biochemical, and echocardiographic variables as predictors of survival in canine patients with myxomatous mitral valve disease and congestive heart failure. Brložnik M, Pečjak A, Nemec Svete A, Domanjko Petrič A. J Vet Cardiol; 2023 Apr 28; 46():18-29. PubMed ID: 37023673 [Abstract] [Full Text] [Related]
5. Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation. Morgan KRS, Monteith G, Raheb S, Colpitts M, Fonfara S. Vet J; 2020 Sep 28; 263():105518. PubMed ID: 32928487 [Abstract] [Full Text] [Related]
6. Inflammation and its association with oxidative stress in dogs with heart failure. Nemec Svete A, Verk B, Čebulj-Kadunc N, Salobir J, Rezar V, Domanjko Petrič A. BMC Vet Res; 2021 Apr 26; 17(1):176. PubMed ID: 33902566 [Abstract] [Full Text] [Related]
7. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study. Boswood A, Gordon SG, Häggström J, Vanselow M, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Schummer C, Watson P. J Vet Intern Med; 2020 May 26; 34(3):1108-1118. PubMed ID: 32200574 [Abstract] [Full Text] [Related]
10. Potential prognostic indicators in dogs with advanced heart failure secondary to myxomatous mitral valve disease. Li CC, Chan IP, Chang CC, Hsueh T, Yang CC, Lin SL. Vet Rec; 2024 Jul 20; 195(2):e4393. PubMed ID: 38959211 [Abstract] [Full Text] [Related]
11. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs. Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M. J Vet Intern Med; 2017 Mar 20; 31(2):316-325. PubMed ID: 28145607 [Abstract] [Full Text] [Related]
12. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease. Caivano D, Rishniw M, Birettoni F, Patata V, Giorgi ME, Porciello F. J Vet Cardiol; 2018 Apr 20; 20(2):102-114. PubMed ID: 29459124 [Abstract] [Full Text] [Related]
13. Usefulness of conventional and tissue Doppler echocardiography to predict congestive heart failure in dogs with myxomatous mitral valve disease. Kim JH, Park HM. J Vet Intern Med; 2015 Jan 20; 29(1):132-40. PubMed ID: 25270196 [Abstract] [Full Text] [Related]
16. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. Hezzell MJ, Boswood A, López-Alvarez J, Lötter N, Elliott J. J Vet Cardiol; 2017 Aug 20; 19(4):325-338. PubMed ID: 28734620 [Abstract] [Full Text] [Related]
17. Neutrophil-to-lymphocyte ratio is increased in dogs with acute congestive heart failure secondary to myxomatous mitral valve disease compared to both dogs with heart murmurs and healthy controls. DeProspero DJ, Hess RS, Silverstein DC. J Am Vet Med Assoc; 2023 Nov 01; 261(11):1-8. PubMed ID: 37406992 [Abstract] [Full Text] [Related]
18. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. Boswood A, Häggström J, Gordon SG, Wess G, Stepien RL, Oyama MA, Keene BW, Bonagura J, MacDonald KA, Patteson M, Smith S, Fox PR, Sanderson K, Woolley R, Szatmári V, Menaut P, Church WM, O'Sullivan ML, Jaudon JP, Kresken JG, Rush J, Barrett KA, Rosenthal SL, Saunders AB, Ljungvall I, Deinert M, Bomassi E, Estrada AH, Fernandez Del Palacio MJ, Moise NS, Abbott JA, Fujii Y, Spier A, Luethy MW, Santilli RA, Uechi M, Tidholm A, Watson P. J Vet Intern Med; 2016 Nov 01; 30(6):1765-1779. PubMed ID: 27678080 [Abstract] [Full Text] [Related]
19. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease. Sargent J, Muzzi R, Mukherjee R, Somarathne S, Schranz K, Stephenson H, Connolly D, Brodbelt D, Fuentes VL. J Vet Cardiol; 2015 Mar 01; 17(1):1-12. PubMed ID: 25586168 [Abstract] [Full Text] [Related]
20. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R. J Vet Intern Med; 2008 Mar 01; 22(5):1124-35. PubMed ID: 18638016 [Abstract] [Full Text] [Related] Page: [Next] [New Search]